Solutions
Advisory Services
Clinical Development
- Generics Development
- Clinical Operations
- Clinical Data Sciences
- Medical and Safety Services
- RWD & RWE Services
Post Marketing
- Safety Services
- Post marketing Studies
- Regulatory Affairs
PV India 2025 once again proved why it remains one of the most sought-after pharmacovigilance peer networks, bringing together senior drug safety leaders for deep, high-quality discussions and future-ready insights. As one of the most established PV peer networks in India, the forum continues to be recognized for its ability to encourage quality di...
On this World Diabetes Day, we reaffirm our global commitment to reducing the burden of diabetes. Because it embodies the science behind better diabetes care, the euglycemic clamp study stands as one of the most significant innovations in modern diabetes research. The euglycemic clamp is a symbol of precision and by offering an accurate measure of ...
Accelerating First-to-Market Success in Generics Bioavailability and Bioequivalence (BABE) studies are critical gateways to bringing safe, effective, and affordable generic medicines to market. With over 90% of US prescriptions filled by generics, ensuring robust clinical execution and data integrity has never been more important. Digital Precision...
The complexities and challenges of data is increasing at an unprecedented rate and excellence in Clinical Data Management (CDM) has become a defining factor of success. Pharmaceutical and biotech companies are looking for partners who not only manage data but transform it into meaningful insights that drive smarter and more compliant decisions. In ...
The second Navitas Life Sciences Ad Promo Roundtable, held on September 25, 2025, convened more than forty experts from across global pharma to examine recent U.S. FDA actions on Direct-to-Consumer (DTC) advertising. Highlights from the Second Ad Promo Roundtable The session was Co-Hosted by Bob Dean, Head of Global Labeling Strategy and Ad/Promo, ...
The pharmaceutical industry is at a turning point in how it manages regulatory submissions. Agencies across the world, from the U.S. Food and Drug Administration (FDA) to the European Medicines Agency (EMA), are demanding structured and timely submissions. Companies that continue relying on legacy publishing systems risk operational bottlenecks, co...
Real World Evidence Market size The healthcare and pharmaceutical landscape is changing at an unprecedented pace. Traditional randomized controlled trials (RCTs), while the gold standard, are not always enough to answer today’s complex clinical questions. This is where real world evidence (RWE), generated from real world data (RWD) such as p...
If you own an API and your next milestone depends on a clean, fast review of your Drug Master File (DMF), this one’s for you. At Navitas Life Sciences, we help sponsors move from document chaos and last-minute firefighting to a predictable, tech-enabled regulatory submission engine, purpose-built for DMFs (drug master file / master drug file...
Real World Evidence: From Data to Decisions The pharmaceutical industry is undergoing a fundamental shift. Traditional randomized controlled trials (RCTs), while critical, often leave gaps in understanding how therapies perform in diverse, real-world settings. Real world evidence (RWE), drawn from real world data (RWD) such as electronic health rec...
What began in 2012 as a conventional regulatory services engagement between Navitas Life Sciences and a Top 5 pharmaceutical company has since evolved into a resilient, forward-thinking partnership, spanning more than a decade. This transformation reflects the power of a model that delivers scalability, flexibility, and sustained excellence in regu...